Article
Medicine, Research & Experimental
Fang-Min Zhong, Fang-Yi Yao, Jing Liu, Mei-Yong Li, Jun-Yao Jiang, Ying Cheng, Shuai Xu, Shu-Qi Li, Nan Zhang, Bo Huang, Xiao-Zhong Wang
Summary: This study investigates the relationship between splicing factors (SFs) and the clinical features and biological processes of AML. The majority of SFs were upregulated in AML samples and associated with poor prognosis. A risk score model was constructed as an independent prognostic factor, and SRSF10 was identified as a potential therapeutic target and biomarker for AML.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Multidisciplinary Sciences
Osvaldo D. Rivera, Michael J. Mallory, Mathieu Quesnel-ValliIres, Rakesh Chatrikhi, David C. Schultz, Martin Carroll, Yoseph Barash, Sara Cherry, Kristen W. Lynch
Summary: In acute myeloid leukemia, alternative splicing events can alter the expression of a subset of genes independently of known somatic mutations. Furthermore, the reduced functional EZH2 in some patients is not solely caused by somatic mutations, indicating a role of aberrant splicing in gene dysregulation.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Hematology
Alex Bataller, Ana Garrido, Francesca Guijarro, Guadalupe Onate, Marina Diaz-Beya, Montserrat Arnan, Mar Tormo, Susana Vives, Maria Paz Queipo de Llano, Rosa Coll, David Gallardo, Ferran Vall-Llovera, Lourdes Escoda, Antonio Garcia-Guinon, Olga Salamero, Antonia Sampol, Brayan M. Merchan, Joan Bargay, Sandra Castano-Diez, Daniel Esteban, Aina Oliver-Caldes, Andrea Rivero, Pablo Mozas, Monica Lopez-Guerra, Marta Pratcorona, Lurdes Zamora, Dolors Costa, Maria Rozman, Josep F. Nomdedeu, Dolors Colomer, Salut Brunet, Jorge Sierra, Jordi Esteve
Summary: The 2017 European LeukemiaNet guidelines for acute myeloid leukemia have been validated in a large cohort of patients and identified a genetic subset with a very poor prognosis.
Article
Hematology
Michael Heuser, Sylvie D. Freeman, Gert J. Ossenkoppele, Francesco Buccisano, Christopher S. Hourigan, Lok Lam Ngai, Jesse M. Tettero, Costa Bachas, Constance Baer, Marie-Christine Bene, Veit Bucklein, Anna Czyz, Barbara Denys, Richard Dillon, Michaela Feuring-Buske, Monica L. Guzman, Torsten Haferlach, Lina Han, Julia K. Herzig, Jeffrey L. Jorgensen, Wolfgang Kern, Marina Y. Konopleva, Francis Lacombe, Marta Libura, Agata Majchrzak, Luca Maurillo, Yishai Ofran, Jan Philippe, Adriana Plesa, Claude Preudhomme, Farhad Ravandi, Christophe Roumier, Marion Subklewe, Felicitas Thol, Arjan A. van de Loosdrecht, Bert A. van der Reijden, Adriano Venditti, Agnieszka Wierzbowska, Peter J. M. Valk, Brent L. Wood, Roland B. Walter, Christian Thiede, Konstanze Dohner, Gail J. Roboz, Jacqueline Cloos
Summary: The European LeukemiaNet MRD Working Party updated the 2018 MRD recommendations, including technical specifications and integrative assessments. They also proposed the use of MRD as a prognostic and surrogate endpoint for drug testing, as well as the clinical implications of MRD assessment in AML. Recommendations include technical requirements for flow cytometry and molecular MRD analysis, as well as reporting methods for MRD results.
Article
Medicine, General & Internal
Eric J. Duncavage, Molly C. Schroeder, Michele O'Laughlin, Roxanne Wilson, Sandra MacMillan, Andrew Bohannon, Scott Kruchowski, John Garza, Feiyu Du, Andrew E. O. Hughes, Josh Robinson, Emma Hughes, Sharon E. Heath, Jack D. Baty, Julie Neidich, Matthew J. Christopher, Meagan A. Jacoby, Geoffrey L. Uy, Robert S. Fulton, Christopher A. Miller, Jacqueline E. Payton, Daniel C. Link, Matthew J. Walter, Peter Westervelt, John F. DiPersio, Timothy J. Ley, David H. Spencer
Summary: This study showed that whole-genome sequencing provided rapid and accurate genomic profiling in patients with AML or MDS, with a greater diagnostic yield than conventional cytogenetic analysis, and more efficient risk stratification based on standard risk categories.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Oncology
Nicholas C. P. Cross, Thomas Ernst, Susan Branford, Jean-Michel Cayuela, Michael Deininger, Alice Fabarius, Dennis Dong Hwan Kim, Katerina Machova Polakova, Jerald P. Radich, Ruediger Hehlmann, Andreas Hochhaus, Jane F. Apperley, Simona Soverini
Summary: The article discusses laboratory management methods for patients with CML, including accurate diagnosis, assessment of prognostic markers, sequential assessment of residual disease levels, and investigation of reasons for resistance, relapse, or progression. The recommendations focus on current best practices and highlight the strengths and pitfalls of commonly used laboratory tests.
Article
Oncology
Krzysztof Mrozek, Jessica Kohlschmidt, James S. Blachly, Deedra Nicolet, Andrew J. Carroll, Kellie J. Archer, Alice S. Mims, Karilyn T. Larkin, Shelley Orwick, Christopher C. Oakes, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Guido Marcucci, Maria R. Baer, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Ann-Kathrin Eisfeld
Summary: Recently, the European LeukemiaNet revised the genetic-risk classification of acute myeloid leukemia (AML), leading to changes in the percentage of patients in different risk groups. The new classification accurately reflected treatment outcomes in most patients, but there were discrepancies in certain age and ethnic groups. The prediction abilities of the new and old classifications were similar, and the significance of some newly added markers was confirmed and challenged.
Review
Oncology
Yotaro Ochi, Seishi Ogawa
Summary: Recent genomic studies have identified chromatin-spliceosome (CS)-acute myeloid leukemia (AML) as a new subgroup of AML defined by mutations affecting epigenetic regulation. CS-AML shares molecular similarities with myelodysplastic syndrome and secondary AML and is associated with poor prognosis, requiring novel therapeutic strategies and stem cell transplantation. Multiple CS-mutations synergistically contribute to the development of severe MDS/AML, highlighting the importance of these mutations in disease progression.
Article
Hematology
Curtis A. Lachowiez, Nicola Long, Jennifer Saultz, Arpita Gandhi, Laura F. Newell, Brandon Hayes-Lattin, Richard T. Maziarz, Jessica Leonard, Daniel Bottomly, Shannon McWeeney, Jennifer Dunlap, Richard Press, Gabrielle Meyers, Ronan Swords, Rachel J. Cook, Jeffrey W. Tyner, Brian J. Druker, Elie Traer
Summary: Risk stratification is important in AML for survival prediction and treatment choice. The 2022 ELN recommendations have updated risk group assignment and it remains unknown how they compare to the 2017 guidelines. This comparative analysis evaluated outcomes in AML patients between the two sets of guidelines and found that the updated ELN 2022 guidelines better stratify survival between intermediate and adverse-risk patients treated with induction chemotherapy.
Article
Biochemistry & Molecular Biology
Carmelo Gurnari, Simona Pagliuca, Valeria Visconte
Summary: Alternative RNA splicing is an essential physiological function that plays a crucial role in cellular development. RNA splicing dysfunction has been implicated in the development of several cancers, including myeloid malignancies. Cancer cells exhibit marked gene expression alterations, including different usage of AS isoforms, potentially causing tissue-specific effects and disruptions of downstream pathways.
Article
Oncology
Christian Rausch, Maja Rothenberg-Thurley, Annika Dufour, Stephanie Schneider, Hanna Gittinger, Cristina Sauerland, Dennis Goerlich, Utz Krug, Wolfgang E. Berdel, Bernhard J. Woermann, Wolfgang Hiddemann, Jan Braess, Michael von Bergwelt-Baildon, Karsten Spiekermann, Tobias Herold, Klaus H. Metzeler
Summary: The revised 2022 European LeukemiaNet (ELN) AML risk stratification system needs to be validated in large cohorts with homogeneous treatment. The study compared ELN-2022 to the previous ELN-2017 risk classification in 1118 newly diagnosed AML patients and validated the key findings in a cohort of 1160 mostly younger patients. ELN-2022 reclassified 15% of patients, with 3% in more favorable and 12% in more adverse risk groups.
Article
Oncology
Ping Ye, Yan Yang, Liqiang Zhang, Guixi Zheng
Summary: This study identified 2,212 AS events significantly associated with overall survival in esophageal carcinoma patients from TCGA database. Prognostic signatures based on these AS events were established through multivariate analysis, with risk score proving to be an independent survival factor. The interaction network between AS events and splicing factors revealed hub genes and AS events warranting further investigation, providing novel insights into tumorigenesis and progression mechanisms of esophageal carcinoma.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Susana Elaine Alves da Rosa, Larissa Barbosa de Lima, Caroline Nunes Silveira, Luiz Gustavo Ferreira Cortes, Joao Bosco de Oliveira Filho, Rodrigo de Souza Reis, Murilo Castro Cervato, Pedro Henrique Sebe Rodrigues, Karla de Oliveira Pelegrino, Roberta Cardoso Petroni, Erica da Silva Araujo, Paulo Vidal Campregher
Summary: This study describes a real-world genomic profiling experience in AML and demonstrates the impact of the European Leukemia Net 2022 update on risk stratification in AML.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Review
Medicine, General & Internal
Dirk Reinhardt, Evangelia Antoniou, Katharina Waack
Summary: This review discusses the key developments in pediatric acute myeloid leukemia (AML) in terms of diagnosis, treatment, risk groups, and outcomes. It also provides a brief overview of current and future approaches.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Public, Environmental & Occupational Health
Zhiwu Wang, Qiong Wu, Yankun Liu, Qingke Li, Jingwu Li
Summary: This study identified prognostic AS events in gastric cancer (GC) and constructed multi-AS-based signatures using RNA-Seq data. The study found that these AS events served as prognostic biomarkers and were correlated with the expression of splicing factors. The findings provide valuable evidence for understanding the prognosis and potential therapeutic targets in GC.
ARCHIVES OF PUBLIC HEALTH
(2022)
Letter
Hematology
Wen Jin, Li Chen, Yabin Liu, Qiusheng Chen, Ming Zhao, Yun Tan, Wei Zhang, Huan Song, Xiangqin Weng, Jianqing Mi, Saijuan Chen, Zhu Chen, Junmin Li, Kankan Wang
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Cell Biology
Xiaofan Liu, Ming Hou, Junmin Li, Jie Jin, Meijuan Huang, Ziqiang Yu, Xiaojun Xu, Xiaohui Zhang, Renchi Yang
Summary: This phase III study evaluated the long-term efficacy and safety of eltrombopag in Chinese patients with chronic ITP. The results from stage 2 showed sustained efficacy and good tolerability of eltrombopag, with a decrease in bleeding events compared to baseline.
Article
Multidisciplinary Sciences
Li Chen, Hong-Ming Zhu, Yan Li, Qi-Fa Liu, Yu Hu, Jian-Feng Zhou, Jie Jin, Jian-Da Hu, Ting Liu, De-Pei Wu, Jie-Ping Chen, Yong-Rong Lai, Jian-Xiang Wang, Juan Li, Jian-Yong Li, Xin Du, Xin Wang, Ming-Zhen Yang, Jin-Song Yan, Gui-Fang Ouyang, Li Liu, Ming Hou, Xiao-Jun Huang, Xiao-Jing Yan, Dan Xu, Wei-Ming Li, Deng-Ju Li, Yin-Jun Lou, Zheng-Jun Wu, Ting Niu, Ying Wang, Xiao-Yang Li, Jian-Hua You, Hui-Jin Zhao, Yu Chen, Yang Shen, Qiu-Sheng Chen, Jian Li, Bing-Shun Wang, Wei-Li Zhao, Jian-Qing Mi, Kan-Kan Wang, Jiong Hu, Zhu Chen, Sai-Juan Chen, Jun-Min Li
Summary: This study found that the combination of all-trans retinoic acid and arsenic trioxide in treating acute promyelocytic leukemia during consolidation therapy is not inferior to traditional chemotherapy regimens and shows better outcomes in reducing relapse and toxicity.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Public, Environmental & Occupational Health
Yuexin Dong, Ba Dun, Pu Bu Wang Dui, Luo Bu Zhuo, Jie Fang, Ci Ren Yang Zong, Zong Ji, Pengpeng Xu, Yu Zheng, Fei Yue, Junmin Li, Xiaoyang Li
WILDERNESS & ENVIRONMENTAL MEDICINE
(2020)
Article
Oncology
Yu Zheng, Yuan-Fei Mao, Hui-Jin Zhao, Li Chen, Li-Ning Wang, Yun-Xiang Zhang, Jiong Hu, Jun-Min Li, Xiao-Yang Li, Hong-Ming Zhu
Summary: This study investigated the arsenic metabolism in APL patients who completed ATO treatment and found a decreased arsenic methylation capacity after treatment. The increased proportion of iAs(III) in urine was associated with chronic liver toxicity, highlighting the importance of monitoring urine PMI and considering SNPs of the AS3MT gene in determining ATO dosage.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Xiaojing Lin, Niu Qiao, Yang Shen, Hai Fang, Qing Xue, Bowen Cui, Li Chen, Hongming Zhu, Sujiang Zhang, Yu Chen, Lu Jiang, Shengyue Wang, Junmin Li, Bingshun Wang, Bing Chen, Zhu Chen, Saijuan Chen
Summary: This study conducted a systematic analysis of genomics and transcriptomics of APL patients to develop a new scoring system (APL9 score), which, combined with NRAS mutations and WBC counts, stratified patients into two groups, with the revised standard-risk group showing significantly better survival rates.
CLINICAL CANCER RESEARCH
(2021)
Letter
Multidisciplinary Sciences
Liang Cheng, Zijun Zhu, Chao Wang, Ping Wang, Yongqun Oliver He, Xue Zhang
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Cell Biology
Xiaoling Wang, Peng Jin, Yi Zhang, Kankan Wang
Summary: This study reveals that circSPI1, a circular RNA derived from the SPI1 gene, is highly expressed in AML and acts as an oncogene, promoting AML development through multiple interactions. CircSPI1 contributes to myeloid differentiation, proliferation, and apoptosis in AML cells by interacting with various factors, showcasing the complexity of SPI1 gene regulation involving circSPI1.
CELL DEATH & DISEASE
(2021)
Article
Immunology
Ran Li, Zuoyou Ding, Peng Jin, Shishuang Wu, Ge Jiang, Rufang Xiang, Wenfang Wang, Zhen Jin, Xiaoyang Li, Kai Xue, Xiaolu Wu, Junmin Li
Summary: The prognosis of acute myeloid leukemia is closely related to changes in immune response. The immune-17 signature established in this study may be a useful model for evaluating AML survival outcomes and improving treatment selection.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Ran Li, Shishuang Wu, Xiaolu Wu, Ping Zhao, Jingyi Li, Kai Xue, Junmin Li
Summary: The study established a prognostic model based on IRL signature for predicting AML patients' overall survival, demonstrating its reliability and effectiveness. The prognostic model, in conjunction with clinical features via a nomogram, improved prognostic accuracy and identified the potential roles of monocytes and metabolism pathways in AML progression.
Article
Biochemistry & Molecular Biology
Ran Li, Xiaolu Wu, Ping Zhao, Kai Xue, Junmin Li
Summary: The study finds that HDAC11 is aberrantly expressed in multiple types of cancer and is associated with prognosis and tumor immunity. HDAC11 is also correlated with tumor mutational burden, microsatellite instability, and drug sensitivity. These findings provide clues for further understanding of the key role of HDAC11 in multiple cancers.
Article
Hematology
Shishuang Wu, Shufen Li, Peng Jin, Yi Zhang, Li Chen, Wen Jin, Junmin Li, Kankan Wang
Summary: Patients with newly diagnosed acute promyelocytic leukemia (APL) often have obesity and metabolic disorders, such as dyslipidemia. This study found that APL patients had higher triglyceride levels than non-APL patients and controls. High triglyceride levels were associated with early death in APL patients and positively correlated with leukocyte counts. The involvement of peroxisome proliferator-activated receptor-alpha (PPAR alpha) in APL proliferation and hyperlipidemia was revealed through RNA sequencing analysis and in vivo experiments. This study sheds light on the link between high triglyceride levels and APL proliferation and provides genetic evidence for PPAR alpha-mediated hyperlipidemia in APL.
Article
Oncology
Peng Jin, Qiqi Jin, Xiaoling Wang, Ming Zhao, Fangyi Dong, Ge Jiang, Zeyi Li, Jie Shen, Wei Zhang, Shishuang Wu, Ran Li, Yunxiang Zhang, Xiaoyang Li, Junmin Li
Summary: In this study, the researchers identified AML-specific fitness genes and developed a prognostic fitness score using CRISPR-Cas9 data. The score showed high prognostic power and improved risk stratification in AML patients. It also helped guide treatment decisions by identifying patients most likely to benefit from chemotherapy and experimental therapies.
CLINICAL CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Weiming Guo, Peng Jin, Ruomei Li, Lu Huang, Zhen Liu, Hairui Li, Ting Zhou, Bing Fang, Lunguo Xia
Summary: In this study, we used the DNB approach to analyze gene expression data in a zebrafish osteoporosis model and identified cdkn1a as a core DNB and an early-warning signal of osteoporosis onset. Functional studies demonstrated that cdkn1a negatively regulates osteogenesis and plays a role in osteoclast differentiation. Mechanistic findings suggested that cdkn1a regulates upstream signaling cascades in osteoclast differentiation.
EXPERIMENTAL AND MOLECULAR MEDICINE
(2023)